This study used Clalit's medical records to compare GLP-1 receptor agonists with SGLT-2 inhibitors in type 2 diabetes and obesity. Target trials were emulated for 4,296 liraglutide, 11,159 dulaglutide and 5,041 semaglutide initiators, with inverse-probability weighting. Five-year weight loss with liraglutide and dulaglutide, at 6.4-7.3 kg, was similar to SGLT-2 inhibitors. At 18 months, semaglutide gave 2.6 kg (95% CI 1.2-4.0) more weight loss than SGLT-2 inhibitors. At 18 months HbA1c fell 0.4%, 0.7% and 0.6% more with liraglutide, dulaglutide and semaglutide, an advantage maintained throughout follow-up. The data are observational, and semaglutide follow-up ran only three years against five for the others.
Why it is interesting: Long-term head-to-head randomised trials of these drug classes are lacking. These analyses extend short-term trial evidence to five years for liraglutide and dulaglutide.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.